[ad_1]
More than 15,000 people took part in the tests in the UK. People ages 18 to 84, Novavax said.
A small-scale study in the Republic of South Africa, where another new variant of the COVID-19 agent was first identified in that country, shows that the vaccine is only 55 percent effective.
VIDEO: The most relevant information about the Johnson & Johnson vaccine is from ICD
According to the results of both studies, the product is 100% effectively protects against severe coronavirus infection.
“We were very inspired by the data that the vaccine not only provided complete protection against the most severe forms of the disease, but also significantly reduced the incidence of mild to moderate morbidity in both studies,” said Stanley Erck, Executive Director. by Novavax.
The company hopes to use this data when requesting approval for its vaccine in various parts of the world.
[ad_2]
